Bax targets mitochondria by distinct mechanisms before or during apoptotic cell death: a requirement for VDAC2 or Bak for efficient Bax apoptotic function
SB Ma, TN Nguyen, I Tan, R Ninnis, S Iyer, DA Stroud, M Menard, RM Kluck, MT Ryan, G Dewson
Cell Death & Differentiation | NATURE PUBLISHING GROUP | Published : 2014
Awarded by National Health and Medical Research Council of Australia
Awarded by Association for International Cancer Research
We would like to thank Stephanie Fennell for technical assistance, Colin Hockings for the Bid and Bim BH3 peptides, Mark van Delft for the FLAG-VDAC2 construct, Gabriela Brumatti for fetal liver extraction, William Craigen for the Vdac2<SUP>+/+</SUP> (wild-type) and Vdac2<SUP>-/-</SUP> MEFs, Richard Youle for the wild-type, BAK<SUP>-/-</SUP> and BAX<SUP>-/-</SUP> HCT116 lines and Boris Reljic for the anti-human VDAC2 antibody. The work was supported by grants from the National Health and Medical Research Council of Australia (637335), and the Association for International Cancer Research (10-230), and operational infrastructure grants through the Australian Government IRISS and the Victorian State Government OIS.